Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy

about

Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy

Item

http://www.wikidata.org/entity/Q58777263

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy

@en

Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy

@nl

type

Item

label

Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy

@en

Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy

@nl

prefLabel

Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy

@en

Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy

@nl

P1476

Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy

@en

P2093

Edzard Schwedhelm

http://www.w3.org/2001/XMLSchema#string

Jefferson Loso

http://www.w3.org/2001/XMLSchema#string

Kathrin Cordts

http://www.w3.org/2001/XMLSchema#string

Maxim Avanesov

http://www.w3.org/2001/XMLSchema#string

Monica Patten

http://www.w3.org/2001/XMLSchema#string

Natalie Lund

http://www.w3.org/2001/XMLSchema#string

Nicole Muschol

http://www.w3.org/2001/XMLSchema#string

Susanne Lezius

http://www.w3.org/2001/XMLSchema#string

P2860

Angiostatin binds ATP synthase on the surface of human endothelial cells

Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.

Establishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease.

MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure.

Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction.

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications

Angiokeratoma corporis diffusum--Fabry disease: historical review from the original description to the introduction of enzyme replacement therapy.

Association of asymmetric dimethylarginine and endothelial dysfunction.

ADMA and oxidative stress.

P304

108

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FCVM.2018.00108

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30159316

http://www.w3.org/2001/XMLSchema#string

P932

6104487

http://www.w3.org/2001/XMLSchema#string